5 Best Biotech Stocks to Buy According to Analysts

In this article, we will be taking a look at the 5 Best Biotech Stocks to Buy According to Analysts. If you wish to see the full list, visit 10 Best Biotech Stocks to Buy According to Analysts.

5. Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Price Target Upside: 63.74%

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the best biotech stocks on this list.

TheFly reported on June 10 that UBS increased its price target on CLDX to $45 from $38 while maintaining a Buy rating on the shares. The firm noted that Barzolvolimab’s Phase 3 chronic spontaneous urticaria (CSU) program has a favorable development outlook and could support a potential approval in 2027.

In addition to that, more recently, on June 14, Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented updated long-term findings from its Phase 2 study of barzolvolimab during a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting. The results showed that barzolvolimab provided rapid and sustained improvements in angioedema symptoms among patients with chronic spontaneous urticaria who had not responded adequately to antihistamine treatment. The benefits remained evident seven months after patients completed dosing, highlighting the potential durability of the treatment effect. The findings further support barzolvolimab’s ability to move CSU treatment beyond symptom management toward disease modification and reinforce continued evaluation in ongoing Phase 3 CSU trials.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a clinical-stage biopharmaceutical company developing antibody therapies for inflammatory and autoimmune diseases, led by barzolvolimab for mast cell–driven conditions.